Zymeworks Inc.
-
Ticker
ZYME
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 201-500 Employees
- Based in Vancouver, British Columbia
Zymeworks (NYSE:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric
…More™ bispecific antibody currently in a registration-enabling clinical trial for refractory HER2+ biliary tract cancer as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
Zymeworks Inc.
Most Recent Responsibility Report
MOST RECENT
2023 ESG Report
Report Locked. Zymeworks Inc. has reached its limit for free report views.
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived Zymeworks Inc. Sustainability Report, Zymeworks Inc. Corporate Social Responsibility Report, Zymeworks Inc. CSR Report, Zymeworks Inc. Corporate Responsibility, Zymeworks Inc. CR Report, Zymeworks Inc. Citizenship Report, Zymeworks Inc. ESG Report, and Zymeworks Inc. Environmental Report online.